Profound academic background:
Bee therapy technology integrating industry, academia and research
Fujian Shenfeng Technology Development Co., Ltd. was established in 1996. Relying on the technical support of the Bee Therapy Research Institute of Fujian Agriculture and Forestry University, it is the first high-tech enterprise in China that integrates beekeeping, bee therapy medical research, bee product development and industrialization. The company takes the College of Apiculture of Fujian Agriculture and Forestry University as its research base and, in collaboration with national-level platforms such as the National and Local Joint Engineering Laboratory for Natural Biological Toxins and the Ministry of Education Research Center for Bee Product Processing and Application, has established an integrated innovation system of "industry-university-research-application".
Shenfeng Technology, with bee venom as its core, has pioneered the industrialization of bee therapy medicine. Its star product, "Divine Bee Essence", is a compound preparation of bee venom. Clinically verified, it has an effective rate of 93.2% for diseases such as intervertebral disc protrusion, cervical spondylosis, and rheumatoid arthritis, far exceeding traditional therapies. Another research product, "Baoyuanling" bee venom anti-cancer preparation, has demonstrated remarkable performance in the treatment of liver cancer, nasopharyngeal cancer and other diseases, and is a key public relations research project of the company's scientific research team.
Shenfeng Technology, with bee venom as its core, has pioneered the industrialization of bee therapy medicine. Its star product, "Divine Bee Essence", is a compound preparation of bee venom. Clinically verified, it has an effective rate of 93.2% for diseases such as intervertebral disc protrusion, cervical spondylosis, and rheumatoid arthritis, far exceeding traditional therapies. Another research product, "Baoyuanling" bee venom anti-cancer preparation, has demonstrated remarkable performance in the treatment of liver cancer, nasopharyngeal cancer and other diseases, and is a key public relations research project of the company's scientific research team.
|
|